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Abstract
The lack of information regarding the metabolism and
pathophysiology of individual tumors limits, in part,
both the development of new anti - cancer therapies and
the optimal implementation of currently available treatments. Magnetic resonance [ MR, including magnetic
resonance imaging ( MRI ) , magnetic resonance spectroscopy ( MRS ) , and electron paramagnetic resonance
( EPR ) ] provides a powerful tool to assess many
aspects of tumor metabolism and pathophysiology.
Moreover, since this information can be obtained non destructively, pre - clinical results from cellular or animal
models are often easily translated into the clinic. This
review presents selected examples of how MR has been
used to identify metabolic changes associated with
apoptosis, detect therapeutic response prior to a
change in tumor volume, optimize the combination of
metabolic inhibitors with chemotherapy and / or radiation, characterize and exploit the influence of tumor pH
on the effectiveness of chemotherapy, characterize
tumor reoxygenation and the effects of modifiers of
tumor oxygenation in individual tumors, image transgene expression and assess the efficacy of gene
therapy. These examples provide an overview of several
of the areas in which cellular and animal model studies
using MR have contributed to our understanding of the
effects of treatment on tumor metabolism and pathophysiology and the importance of tumor metabolism
and pathophysiology as determinants of therapeutic
response. Neoplasia (2000) 2, 152 ± 165.
Keywords: nuclear magnetic resonance, neoplasms, pathophysiology, metabolism,
therapy.

Introduction
The development of new anti - cancer therapies and the
optimal implementation of currently available treatments are
limited, in part, by the lack of information regarding the
metabolism and pathophysiology of individual tumors.

Availability of this metabolic and physiologic information for
individual tumors could be used in a variety of ways including
the following 1 ) It could guide the development of new
strategies to manipulate tumor physiology and / or metabolism for therapeutic advantage, 2 ) It could allow the effects of
treatment on tumor pathophysiology to be considered in
scheduling multi - course or multi - modality treatment, 3 ) It
may allow use of changes in tumor pathophysiology evident,
prior to changes in tumor size, to detect tumor response to
therapy in individual patients early in the course of treatment.
One promising method to non - invasively assess tumor
physiology and metabolism, which can be applied to cell
and animal models and is also already widely available
clinically, is magnetic resonance ( MR ) .
Magnetic resonance imaging ( MRI ) , magnetic resonance
spectroscopy ( MRS ) , and electron paramagnetic resonance
( EPR ) can non - invasively provide a wealth of information
regarding tumor metabolism and pathophysiology. Moreover,
because MR provides information regarding in vivo tumor
metabolism and pathophysiology non - destructively, pre clinical results from cellular or animal models are often easily
translated into the clinic. This review presents selected
applications to give the reader an overview of several of the
areas in which cellular and animal model studies using MR
have contributed to our understanding of the effects of
treatment on tumor metabolism and pathophysiology and the
importance of tumor metabolism and pathophysiology as
determinants of therapeutic response. A companion review
[ 1 ] focuses on the use of MR to investigate tumor biology and
physiology in the absence of treatment.
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MR and Apoptosis
Apoptosis, or programmed cell death, is a physiological,
genetically controlled and morphologically defined process
of cell suicide. It is required for the normal development of
multicellular organisms, essential, for example, in embryonic morphogenesis or lymphocyte selection. First described on the basis of morphological observations [ 2 ] ,
the precise mechanism and genetic regulation of apoptosis are still under investigation ( Ref. [ 3 ] and references
therein ) . In the context of cancer, however, it is now clear
that cell death following chemotherapeutic treatment will
occur, in most cases, by apoptosis [ 4 ] . Conversely,
resistance to chemotherapy can be affected by the
expression of genes regulating the apoptotic pathway.
Non - invasively identifying MR signals that are correlated
with programmed cell death could therefore be useful both
in contributing to the understanding of apoptosis and in
helping assess tumor response in vivo. To date, however,
most MR studies of apoptosis have investigated in vitro
cell systems.

Membrane Changes Associated with Apoptosis
End - stage apoptosis is characterized by cell shrinkage,
blebbing and shedding of apoptotic bodies, as well as
alterations in the distribution of phospholipids within the
plasma membrane. Cell shrinkage can be monitored by
using diffusion - weighted 1H MRS to assess changes in
intracellular volume [ 5,6 ] . Other 1H MRS studies have
also identified increases in cellular fatty acid signals
( resonating at 1.3, 2.8 and 5.4 ppm ) . These have been
attributed either to a decrease in membrane microviscosity
during apoptosis or to an increase in intracellular
triglycerides and free fatty acids following activation of
phospholipase A2 during cell death [ 7,8 ] . Further
changes in cellular lipid metabolism during apoptosis have
been identified using 31P MRS. A significant drop in
phosphocholine ( PCho ) has been observed in several
different cell lines following apoptosis induced by various
chemotherapeutic treatments [ 8 ± 13 ] . In HL - 60 cells, the
drop in PCho was also accompanied by an accumulation
of CDP - choline and an inhibition of the CDP - choline:
1,2 - DAG cholinephosphotransferase, possibly due to
cellular acidification during apoptosis [ 10 ] . No accumulation of CDP - choline was observed in other cell lines. In
MCF - 7 cells, the drop in PCho was due to inhibition in
choline uptake followed by an increase in activity of the
CTP:PCho cytidyltransferase [ 14 ] . In contrast to these
observations, an increase in PCho signal was observed in
TNF - induced apoptosis in neutrophils [ 15 ] . PCho could
be generated as the by - product of sphingomyelin breakdown to produce ceramide Ð a possible second
messenger in TNF as well as fas - induced apoptosis.
However, in fas - induced apoptosis of Jurkat cells, no
increase in PCho content or drop in sphingomyelin could
be observed [ 9 ] , further contributing to the current
controversy regarding the involvement of ceramide in
apoptotic signaling.
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Energetic Changes Associated with Apoptosis
Apoptosis is an energy - requiring process. At the same
time, it is now clear that cytochrome C release from the
mitochondria is an important step in the apoptotic cascade,
possibly diminishing the cell's ability to generate ATP. How
cellular ATP stores evolve during apoptosis is therefore an
interesting question and 31P MRS could be useful in
providing an answer. Some researchers have observed an
initial transient increase in cellular nucleoside triphosphates
( NTP, predominantly ATP ) content during apoptosis
[ 16,17 ] possibly explained by upregulation of bcl2 in some
cell lines following treatment. In contrast to these results,
several studies have observed a steady decrease in cellular
ATP following induction of cell death ( Refs. [ 9,11 ± 13 ] ; see
Figure 1 ) . This drop in ATP has been correlated in most
cases with a reduction in cellular NAD / H, and it remains
unclear whether ATP is primarily consumed by the cell to
replenish its NAD / H stores or whether the drop in high energy phosphates reflects their utilization in apoptosis.
Finally, in several cell systems, the drop in NAD / H content
during apoptosis was accompanied by an accumulation of
glycolytic intermediates, in particular fructose - 1,6 - bisphosphate ( see Figure 1; Refs. [ 9,12,13 ] ) . This is due to
activation of the enzyme poly( ADP - ribose ) polymerase

Figure 1. 1H - decoupled 31P MR spectra of extracts from ( A ) control L1210
cells and ( B ) apoptosing L1210 cells following 3 hours of treatment with 50
M nitrogen mustard. Spectra were acquired on a 250 - MHz Bruker
spectrometer and are the result of 10,000 fully relaxed scans plotted with a
line broadening of 0.5 Hz. F -1, 6 - P: fructose -1, 6 -bisphosphate; G - 3 - P:
glycerol - 3 - phosphate; DHAP: dihydroxyacetone phosphate.
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( PARP ) following chemotherapy - induced DNA damage.
Activated PARP consumes NAD, the depletion of which
leads to inhibition of the glycolytic enzyme glyceraldehyde 3 - phosphate dehydrogenase leading to the accumulation of
fructose - 1,6 - bisphosphate as well as other intermediates.
In spite of some promising in vivo results [ 8 ] , the
usefulness of MR techniques in identifying apoptosis in
patients still needs to be confirmed. In vivo, not only is the
spectral resolution lower, but apoptosing cells are rapidly
phagocytosed. In most cases, only a small proportion of
apoptotic cells is present at any one time ( e.g., see Ref.
[ 18 ] ) . The spectra recorded from a treated tumor would
therefore include a relatively small contribution from the
apoptotic fraction. Nonetheless, MR techniques can clearly
be useful both in monitoring changes such as cell shrinkage,
already known to occur during apoptosis, and in identifying
metabolic changes that had not been previously reported.

Early Detection of Therapeutic Response
Traditional methods for detection of therapeutic response
generally rely on a gross decrease in tumor size ( often
measured radiographically using two orthogonal dimensions ) . Although these methods are useful for assessing
response at the end of treatment, little information is
available early in the course of treatment ( i.e., success or
failure of therapy generally takes 2 to 4 months to become
apparent ) . Consequently, patients with non - responsive
tumors receive a full - course of toxic therapy without benefit.
Hence, the need for early predictors of tumor responsiveness applicable to commonly used therapeutic modalities
has long been recognized. Such a predictor would not only
allow patients with non - responsive tumors to avoid the side
effects and toxicity of a full - course of therapy, they could aid
in the selection and evaluation of patients participating in
clinical trials of new anti - tumor therapies.
One approach being evaluated as an early - response
predictor is to assess tumors before and during treatment in
an attempt to detect changes in the pathophysiology of
tumors responding to the initial therapy. Because of the
ability of MR to non - invasively evaluate tumor metabolism
and physiology [ 1 ] , several MR - based methods have been
evaluated for their ability to detect treatment - induced
changes occurring within the tumor prior to a decrease in
tumor size. Ideally, one would like to be able to detect such
changes at the highest possible spatial resolution to permit
intra - tumor heterogeneity to be assessed. This section
reviews two imaging - based methods with sufficient spatial
resolution to assess macroscopic heterogeneity, measurement of water diffusion and dynamic contrast - enhanced
MRI ( DCE - MRI ) , which probe different aspects of tumor
pathophysiology.
Diffusion MR
Water self - diffusion measured by pulsed - field gradient
MR [ 19 ] is influenced by the restriction of diffusion due to the
limited permeability of cell membranes to water [ 20 ] . Hence,
the water self - diffusion coefficient measured by MR is

referred to as the apparent diffusion coefficient ( ADC ) and
is sensitive to biophysical characteristics of tissue, including
the fraction of water in the extracellular space [ 21 ] .
Commonly used anti - cancer agents are cytotoxic, resulting
in tumor cells shrinking ( apoptosis ) or rupturing ( necrosis )
Ð both processes that should increase the extracellular
water fraction. Since both radiation [ 22 ] and chemotherapy
[ 23 ] have been shown to substantially increase the fraction
of extracellular water, tumor water ADC should be altered by
treatment. If these changes are evident prior to a decrease in
tumor size, diffusion MRI could provide a clinically applicable
response predictor since diffusion MRI has been applied to
human brain tumors [ 24,25 ] , breast [ 26 ] , liver [ 27 ] ,
pancreas [ 28 ] , and kidney [ 29 ] .
Treatment response studies thus far have employed
rodent tumor models. A dose - dependent, reversible increase in tumor water ADC was observed in RIF - 1 tumors
( a murine fibrosarcoma ) within 2 days of treatment with
cyclophosphamide [ 30 ] . Even in these RIF - 1 tumors
treated with doses of cyclophosphamide producing an
estimated tumor cell kill of 67%, tumor water ADC increases
substantially at a time when there is essentially no change in
tumor volume. In rat intracranial 9L gliomas treated with a
dose of BCNU resulting in an estimated 90% cell kill, tumor
water ADC increased substantially within a week of treatment, while the tumor volume doubled over that time [ 31 ] .
Ganciclovir treatment of BT4C rat gliomas sensitized by
thymidine kinase - mediated gene therapy ( see Gene Therapy section ) increased tumor water ADC within 4 days after
treatment, although tumor growth continued over that period
[ 32,33 ] . Taxol treatment of MCF - 7 / s ( taxol - sensitive ) and
MCF - 7 / d40 ( taxol - resistant ) human breast cancer xenografts growing in mice increased tumor water ADC only in the
drug - sensitive MCF - 7 / s tumors [ 34 ] . For chemically
induced rat mammary tumors treated with 100 mg kg 1 5 fluorouracil ( 5 - FU ) , although all tumors decreased significantly in volume over the first 7 days after treatment, tumors
with a high initial ADC started to regrow after 7 days [ 35 ] .
Collectively, these results provide strong support for the
potential of tumor water ADC measurements to provide a
sensitive early indicator of response to cytotoxic therapy.
Since each patient's tumor is unique, for ADC measurements to be clinically useful as an early response indicator,
the relationship between drug efficacy and the change in
ADC ( the effective ``dose ± response'' relationship ) should
not depend on the tumor. Because experimental conditions
that can alter the dependence of ADC on the tumor
biophysical characteristics vary among laboratories, it is
difficult to compare results between laboratories. Consequently, the effects of 5 - FU on tumor water ADC measured
using the same experimental parameters were examined in
three different murine tumors [ RIF - 1 and two colon
adenocarcinomas, Colon - 26 and Colon - 38 [ 36 ] ] . A comparison of the therapeutic response [ assessed by the
specific tumor growth delay, STGD [ 37 ] ] and corresponding
maximum ADC changes indicates a strong ``dose ±
response'' relationship for all three tumors ( see Figure 2 ) .
Considering the RIF - 1 cyclophosphamide data with these
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Figure 2. Relationship between the ``dose'', as indicated by the therapeutic
effect ( or STGD ) , and the ``response'', as indicated by the maximum increase
in tumor water ADC for two chemotherapeutic agents ( cyclophosphamide
and 5 - FU ) and three tumor lines ( RIF - 1, Colon - 26 and Colon - 38 ) .

results, it appears the relationship between the maximum
change in ADC and therapeutic effect may be independent of
the cytotoxic agent, as well as the tumor. These observations
support the hypothesis that changes in ADC induced by
cytotoxic therapy are associated with changes in tumor
pathophysiology due to cell death and are directly related to a
therapeutic response. Hence, MR measurements of tumor
water ADC for early detection of response to cytotoxic
therapy should be generally applicable.
DCE - MRI
As described in the companion article [ 1 ] , information on
several aspects of tumor vascularity ( e.g., blood volume,
perfusion, permeability ) can be derived from analysis of the
intra - tumor kinetics of MR contrast agents obtained using
DCE - MRI. Since this technique is non - invasive, the tumor
can be monitored longitudinally over a period of time to study
the changes in tumor vascularity occurring during growth and
alterations induced by various kinds of therapy. Initial results
in the clinic using the low molecular weight agent, Gd - DTPA,
indicate that DCE - MRI may be valuable for both diagnosis
[ 38,39 ] and prognosis [ 40,41 ] of cancer. While these
results suggest that there are substantial physiologic
differences ( i.e., between benign and malignant, or between
non - responsive and responsive tumors ) , the clinically
approved low molecular weight agent does not distinguish
between changes in perfusion and permeability. Hence,
larger molecular weight contrast agents, which can provide
an independent measure of vascular permeability, may
provide additional critical information. Since they are not yet
clinically approved, the ability of these large molecular
weight contrast agents to provide an early indication of
treatment response has been studied in rodent tumor
models.
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DCE - MRI with large molecular weight contrast agents
indicates changes in tumor vascularity early after treatment
for several treatment modalities. In R3230 mammary
adenocarcinomas, vascular permeability to albumin - Gd DTPA is elevated significantly in irradiated tumors compared
to control non - irradiated tumors [ 42,43 ] . In these same
tumors, the vascular volume measured by a macromolecular
agent gadomer - 17 ( molecular weight 35 kDa ) stays
constant over 2 weeks in control tumors despite its rapid
growth [ 44 ] . After treatment with a combination of mitomycin - C and flavone acetic acid, the mean vascular volume
decreased by 42% in responders after a week and further
down to 56% in week 2 [ 44 ] .
In another study, DCE - MRI was used to examine the
effects of using cytokine therapy to modulate the allogenic
rejection of C6 glioma cells implanted subcutaneously into
Wistar rats ( see Table 1 ) . Adenoviruses expressing mouse
interleukin 1 - ( IL1 - ) , mouse interferon ( IFN - ) , and
human transforming growth factor
( TGF - ) were intratumorally injected into three rats, one from each kind.
Although the tumor size in both control and rIL - 1 - infected
animals increased at day 4 ( + 72% and + 140%, respectively ) , the vascular volume of control tumors decreased by
62% ( compared to baseline ) , while the rIL - 1 - inoculated
animal had an increase of 41%. These changes of vascular
volume at day 4 were predictive of tumor growth several days
later. At day 7, the size of control tumors had decreased by
40% while that of the rIL - 1 - infected tumors increased by
159%. The predictive value was valid for both unmodulated
allogenic tumor rejection and when there was modulation of
an immune response ( the rIL1 - - treated animal ) , resulting
in a delayed onset of tumor rejection. Immune modulation
that increased the immune response ( rTGF - and rIFN - )
resulted in an accelerated tumor rejection which prevented
the evaluation of vascular volume as a predictive tool. These
studies support the use of DCE - MRI as a practical tool in the
assessment of tumor vascularity to evaluate therapeutic
response. As macromolecular contrast agents become more
widely available for clinical use, non - invasive evaluation of
changes in vascular volume following cancer therapy can be
performed.

Biochemical Modulators of Therapeutic Response
Cell kill for most commonly used chemotherapeutic agents is
thought to occur by damage to DNA [ 45 ] ; historically, most
chemotherapeutic agents have focused on inhibition or poor

Table 1. The Percentage Change in Tumor Size and the Volume ( V b ) in
Control and Gene - Therapy - Treated Tumors.
Group

Percent Change in Tumor Volume Percent Change ( V b )
Day 4 / Day 0

Control
IL1 -

Day 7 / Day 4

Day 4 / Day 0

+ 72

40

62

+ 140

+ 159

+ 41

TGF -

80

83

NA

IFN -

94

100

NA
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fidelity of DNA reproduction. Recent studies have suggested
that other targets for anti - tumor agents, such as the tumor
vasculature, microtubular structure, cell membrane, intracellular milieu, pH, or metabolic pathways, could enhance tumor
destruction or inhibit proliferation. A novel approach to
treating tumors is to use traditional chemotherapeutic agents
in combination with drugs aimed at interfering with tumor
metabolism, i.e., agents that inhibit glycolysis, aerobic
metabolism, etc. These agents often have limited, if any,
activity by themselves, but can potentiate the effect of other
drugs or radiation. Examples of these agents include 2 deoxyglucose ( 2 - DG ) , lonidamine ( LON ) , and 6 - aminonicotinamide ( 6 - AN ) .
6 - Aminonicotinamide
6 - AN, an analogue of niacin, is currently being evaluated
in pre - clinical trials as part of a combination chemotherapy
and as a radiosensitizer [ 46 ± 49 ] . Although 6 - AN was
evaluated in clinical trials about 40 years ago and lacked
efficacy [ 50 ] , in vitro studies have shown 6 - AN to sensitize
cells to radiation [ 51 ] cis - platinum [ 52 ] and 1,3 Bis ( 2 chloroethyl ) - 1 - nitrosourea ( BCNU ) [ 53 ] . 6 - AN acts by
competition with niacin in pathways utilizing NAD ( P ) , being
metabolized to 6 - ANAD ( P ) . 6 - ANAD ( P ) , in turn, can act
as a competitive inhibitor of NAD ( P ) requiring processes. 6 ANADP is a particularly potent inhibitor of the PPP enzyme,
6 - phosphogluconate ( 6 - PG ) dehydrogenase, which is an
important step in the synthesis of NADPH and ribose units
required for biosynthesis and DNA repair. Inhibition of this
enzyme by 6 - AN leads to accumulation of 6 - PG which
inhibits glycolysis. Therefore, 31P MRS studies of tumor
metabolism should detect a decrease in NTP and phosphocreatine ( PCr ) due to inhibition of glycolysis and possibly
detect 6 - PG, which is distinguishable from naturally occurring phosphoethanolamine.
Keniry et al. [ 54 ] used 31P MRS to study 6 - AN in vitro
in combination with gossypol, another metabolic inhibitor,
and found that it abolished the metabolic effects of
gossypol. They were unable to resolve 6 - PG in the whole
cell spectra [ 54 ] . Subsequent studies have investigated
the effect of 6 - AN in combination with 6 - methyl mercaptopurine riboside ( MMPR ) plus N - ( phosphonacetyl ) - L aspartate ( PALA ) in vivo. PALA decreases pyrimidine
synthesis [ 55 ] , MMPR decreases purine synthesis [ 56 ] ,
and 6 - AN inhibits the PPP and glycolysis and therefore,
this combination should inhibit multiple metabolic processes and enhance tumor cell kill by anti - neoplastic
agents. The combination of these three drugs decreases
the NTP to inorganic phosphate ( Pi ) ratio and the PCr to
Pi ratio at 3, 10 and 24 hours [ 49 ] . Based on these
findings, it was hypothesized that depletion of energy at 10
hours posttreatment with the three - drug combination would
enhance response to radiation. This was evaluated by
treating mice bearing first - generation transplants of the
spontaneous CD8F1 mammary carcinoma with three
cycles of either PALA, MMPR, and 6 - AN, followed by
three 15 Gy fractions, or PALA, MMPR, 6 - AN, and 15 Gy
given three times. This tumor model, which has a 100%

correlation with human breast cancer with regards to
response to chemotherapy [ 57 ] , had never been cured
by any previous treatments. Neither the chemotherapy nor
radiation alone induced any long - term complete remissions ( CR ) ; only one brief CR was noted. However, the
combination of PALA, MMPR, 6 - AN, and 15 Gy given
three times resulted in a 65% complete response rate with
25% of the tumor - bearing mice without recurrence at
greater than 1 year, representing a likely cure of these
tumors. Subsequent investigations of the effect of single agent 6 - AN as a potential radiation sensitizer in vivo
detected 6 - PG and demonstrated efficacy, although
inferior to the three - drug combination [ 48,49 ] .
Mechanistic studies of the effect of 6 - AN on tumor
metabolism were conducted in RIF - 1 cells [ 47 ] . Using 13C
and 31P MRS, perfused RIF - 1 cells were studied after
treatment with 40 M 6 - AN. 6 - PG was detected by both 31P
and 13C MRS ( see Figure 3A and B ) . Figure 3A demonstrates 31P MR spectra indicating a decrease in PCr and NTP
and an increase in 6 - PG after treatment with 6AN. The 13C
MRS studies showed that after 6 - AN, 6 - PG and 6 phosphoglucono - D - lactone ( 6 - PGL ) were detected ( Figure 3B ) , while glucose consumption and lactate production
were decreased ( not shown ) . Enhancement of radiation
only occurred when 6 - AN was given before radiation and not
the reverse sequence, indicating that the metabolic effect of
6 - AN was necessary for radiation enhancement. It was not
clear, however, whether inhibition of the pentose phosphate
pathway ( PPP ) or glycolysis induced radiosensitization. 1H
MRS quantitation of the relative inhibition of glycolysis and
PPP indicated that 6 - AN primarily inhibited glycolysis. These
studies reflect the translational potential of MR in studying
metabolic inhibitors as potential anti - neoplastic agents or
sensitizers [ 47 ] and as potentially valuable tools for clinical
and preclinical studies.
Lonidamine
LON is a metabolic inhibitor which has been shown to
enhance radiation and hyperthermia. Ben - Horin et al. [ 58 ]
have used 31P and 13C MRS to study perfused MCF - 7 cells.
Lonidamine induced intracellular acidification accompanied
by ATP depletion, decreased glucose accumulation, and
increased lactate accumulation. They concluded that the
mechanism of action of this drug is via inhibition of lactate
transport. Ben - Yoseph et al. [ 59 ] studied 9L glioma cells
and also noted acidosis and decreased NTP without any
effect on tumor blood flow after treatment with LON. They
concluded that LON inhibits lactate efflux leading to cellular
acidification.
2 - Deoxyglucose
2 - DG is a glucose analogue that competitively inhibits
both transport and metabolism of glucose. It is phosphorylated intracellularly and is thought not to undergo further
metabolism and inhibits glycolysis. Karczmar et al. [ 60 ]
have used 2 - DG to deplete ATP and found that it did not
affect brain bioenergetics. Kaplan et al. [ 61,62 ] studied
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Figure 3. ( A ) 31P MR spectra of perfused RIF - 1 tumor cells obtained during
the first 1 to 5, 6 to 10 and 11 to 15 hours of perfusion with 40 M 6 - AN. Peaks
are identified as follows: 1 = 6PG, 2 = phosphoethanolamine, 3 = PCho, 4 = Pi,
5 = phosphodiesters, 6 = PCr, 7, 8, and 9 are - , - , and - NTP. Over the
course of the infusion, PCr and - NTP decrease and 6PG, which is not
present initially, increases to become the dominant peak in the spectrum. Note
that the Pi peak is primarily from the perfusate. ( B ) 13C MR spectra of RIF - 1
cells immediately ( bottom ) and 2 hours after ( top ) perfusion with 40 M 6 AN and 1 - 13C glucose. Two peaks, assigned to 6PG and 6 - phosphoglucono - D - lactone, are detected both during and after perfusion and in perchloric
acid extracts ( not shown ) .

multi - drug resistance using 2 - DG. 13C and 31P MRS data
showed that multidrug - resistant ( MDR ) cells accumulate
more 2 - DG and at a faster rate than wild - type ( WT ) cells.
They suggested that this difference could be used therapeutically and subsequently showed that 2 - DG was more
toxic to MDR cells than wild type cells. In contrast,
Rasmussen et al. [ 63 ] have also used 2 - DG to study
glycolytic rates and have shown that MDR Ehrlich ascites
cells do not show enhanced glycolysis compared to wild
type, suggesting that further studies are necessary to resolve
this issue which may have therapeutic significance. Further
studies to address the critical questions of selectivity and
toxicity are necessary.
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Influence of Tumor pH on Effectiveness of Chemotherapy
Tumors have long been known to exhibit aerobic glycolysis,
generating lactic acid even in the presence of oxygen [ 64 ] .
As a consequence of this phenomenon, tumors have
traditionally been thought of as acidic tissues. Direct
measurement of pH in a variety of solid tumors by use of
microelectrodes has strengthened this viewpoint [ 65 ] . As
discussed in the companion article [ 1 ] , in vivo 31P MRS
permits the simultaneous non - invasive measurement of
intracellular pH ( pHi ) and extracellular pH ( pHe ) in tumors
using endogenous inorganic phosphate ( Pi ) and exogenous
3 - aminopropylphosphonate ( 3 - APP ) , respectively. Measurement of pHi and pHe by this method in solid tumor
xenografts has shown that the pHi of tumor cells is neutral to
alkaline while the pHe of the same tumors is acidic [ 66,67 ] .
This pH gradient can impact the effectiveness of chemotherapy. The plasma membrane of cells is more permeable
to the uncharged forms of ionizable drug molecules
compared to their charged forms, especially for lipophilic
species. Thus, while the uncharged form of the drug tends to
equalize in concentration across both sides of the plasma
membrane, the charged form of a weak - base species exists
in higher concentration on the more acidic side of the
membrane, leading to an accumulation of the drug in the
more acidic compartment. This phenomenon is sometimes
referred to as ``ion - trapping'' [ 68 ] . Cells in a tumor can
maintain acid - outside plasmalemmal pH gradients of up to
0.5 pH units [ 69 ] . Some commonly prescribed anti neoplastic agents, such as the anthracyclines, have acid
dissociation ( pK a ) constants of 7.5 to 8.5. For such drugs,
acid - outside plasmalemmal pH gradients of 0.5 pH units can
lead to a 50% reduction in intracellular drug levels as
compared to extracellular drug levels, conferring a form of
``physiological drug resistance'' upon the tumor [ 70,71 ] .
Abolishing or reversing the direction of the plasmalemmal pH
gradient in tumors in vivo therefore should be an attractive
means of enhancing the effectiveness of weak - base
chemotherapeutic agents.
Bicarbonate can Alkalinize Tumors
Sodium bicarbonate ( NaHCO3 ) has been used in
humans to treat metabolic acidosis resulting from renal
failure [ 72 ] or to alleviate exercise - induced acidosis [ 73 ] ,
and has been shown to effect modest increases in blood
pH. For alkalosis to result in improved effectiveness of a
weak - base drug, the subject should be able to tolerate
doses of NaHCO3 sufficient to produce meaningful increases in tumor pHe. MCF7 tumor - bearing SCID mice
tolerated ad libitum water containing 200 mM NaHCO3 for
periods of up to 90 days continuously and gained weight at
rates similar to control mice [ 74 ] . Representative 31P
spectra of MCF - 7 tumors grown in SCID mice treated or
untreated with NaHCO3 are shown in Figure 4. For the
tumor in the control mouse, the pHe measured by 3 - APP is
6.93 and the pHi measured by Pi is 7.29. In the tumor in the
bicarbonate - treated mouse, the 3 - APP resonance is
shifted relative to controls, indicating a significant alkaliniza-
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deleterious effects of chronic denial of fresh water. For the
very same reasons, acute alkalinization should also have
greater clinical utility than chronic treatment with sodium
bicarbonate.

Figure 4. 31P MR spectra of MCF7 tumors grown as xenografts in the
mammary fat pads of female SCID mice. 3 - APP: 3 - aminopropylphosphonate; PME: phosphomonoesters; Pi: inorganic phosphate; NTP: nucleoside triphosphates. Representative spectra from a control mouse given normal
drinking water and a mouse provided ad libitum water containing 200 mM
NaHCO3 are shown.

tion of pHe, while all other resonances ( Pi, PME, NTP ) are
statistically indistinguishable from the control. In this
example, the measured pHe was 7.76. The maximum
measured pHe in normal hind leg tissue in bicarbonate treated SCID mice was 7.67 compared to an average
measured pHe of 7.39 in control mice. Thus, chronic oral
administration of NaHCO3 resulted in significantly greater
alkalinization of tumor tissue than normal tissue, and this
provides a method to increase the chemotherapeutic index
of weak - base drugs.
Sodium Bicarbonate Chemosensitizes Tumor Xenografts
In Vivo
According to the measured plasmalemmal pH gradients,
the theoretical cytosolic - to - extracellular partition ratio for
doxorubicin in tumors should be 1.7 in bicarbonate - treated
animals, and 0.55 in control animals, leading to a 3.1 - fold
increase in tumor sensitivity to doxorubicin [ 71 ] . Similarly,
the calculated doxorubicin partition ratio for normal tissue is
1.9 in bicarbonate - treated animals and 1.6 in control
animals, leading to a 1.2 - fold increase in sensitivity of
normal tissue to doxorubicin. Thus, bicarbonate treatment
can potentially yield a 2.6 - fold increase in the chemotherapeutic index of doxorubicin. Indeed, combination therapy of
MCF7 tumor - bearing SCID mice with doxorubicin and 200
mM NaHCO3 resulted in a significantly reduced tumor growth
rate in those mice as compared to tumors in mice treated
with doxorubicin alone, while bicarbonate alone had no effect
on the tumor growth rate [ 74 ] . Prolonged treatment with
sodium bicarbonate in the drinking water did not have
significant effects on animal well being. In mice, the lifetime
of free drug is on the order of 1 hour following intravenous
delivery [ 75 ] . Therefore, acute metabolic alkalinization with
sodium bicarbonate lasting 1 ± 2 hours should enhance drug
uptake into tumor cells while sparing the host animal the

Radiation and Tumor Oxygenation
Measurements of tumor oxygenation and changes in tumor
oxygenation are crucial to an understanding of tumor
physiology and response to therapy. The oxygen tension in
tumors is a key determinant of the sensitivity of tissues to
ionizing radiation and to certain chemotherapeutic agents
[ 76 ] . For many years, the occurrence of hypoxia in tumors
has been postulated to be a limiting factor in the response to
radiation therapy [ 77 ] and recent results using the Eppendorf electrode system to measure pO2 have confirmed that
this can occur in human tumors [ 78,79 ] . In addition to
quantitative oxygen measurements made using oxygen
electrodes, a variety of spectroscopic methods have been
used. Some of these are based on the use of fluorescent and
phosphorescent probes which are sensitive to oxygen
tension. Others are based on spectroscopic differences
between deoxyhemoglobin and oxyhemoglobin. Although
these methods offer some advantages, none of them is used
routinely and their invasiveness and / or poor spatial resolution has encouraged increased emphasis on the development of magnetic resonance methods sensitive to oxygen
tension.
Some magnetic resonance methods are quantitative,
directly measure tumor pO2, and may allow identification of
hypoxic tumor regions and accurate measurement of
changes in pO2 during therapy. One very promising method
is based on 19F MRI of signals from perfluorocarbons after
either intravenous or intratumoral injection [ 80,81 ] . As
described in the companion review [ 1 ] , the T 1 relaxation
time of the fluorine nucleus in these molecules is sensitive to
local oxygen tension, and since relatively large amounts of
fluorine - containing molecules can be injected, images with
reasonable spatial resolution can be obtained. Another
approach, in vivo electron paramagnetic resonance ( EPR )
oximetry with particulate materials, can provide repeated
non - perturbing measurements from the same site [ 82 ] .
EPR oximetry is based on the fact that the presence of
molecular oxygen affects the linewidth of paramagnetic
materials. This effect is especially useful in lines that are
intrinsically narrow or have mechanisms that involve factors
in addition to those mediated simply by changes ( decreases ) in relaxation times. The effects of oxygen on
linewidths of carbon - based particulates derived from coals
or chars are especially large at low concentrations of oxygen,
making these materials particularly suitable for oximetry in
tumors where the pO2 values of most interest are quite low
( in the range of 0 to 10 Torr ) .
Another MR approach, which makes use of proton
( water ) MRI, relies on blood - oxygen - level - dependent
( BOLD ) contrast. The large paramagnetic susceptibility of
deoxyhemoglobin generates large magnetic field gradients
in and around blood vessels which effect the linewidth ( or
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T 2* relaxation time ) of the water proton signal. This does
not allow quantitative measurement of the oxygen level,
except in large veins, because there are many other
important influences on the water proton signal. However,
BOLD MRI can provide a qualitative indication of changes in
tumor oxygenation. Equipment used to obtain BOLD MRI
measurements is widely available both for clinical measurements in cancer patients and for studies of animal models.
Tumor Reoxygenation
A dose of radiation kills oxygenated cells more efficiently,
leaving a greater proportion of hypoxic cells that tend to
reoxygenate in many animal tumors and human xenografts
[ 83 ] . It has been suggested that one of the reasons
fractionated radiation is successful is that tumor reoxygenation occurs after each dose. Consequently, the tumor is well oxygenated at the time of subsequent doses, while the
effects on normal tissues are not altered because they
already are fully oxygenated in terms of responses to
radiation [ 84 ] . Different tumor types and different individual
tumors, however, may fail to reoxygenate or may have
altered timing of post - radiation changes in pO2. It then
follows that if methods were available to assess tumor
oxygenation status repeatedly and accurately, more effective radiation treatments could be carried out by timing
radiation doses to take advantage of reoxygenation. Those
tumors that fail to reoxygenate and thus are unlikely to
respond to irradiation could be treated with another modality
without having to wait for the current endpoint, which is a
failure to respond adequately to the full course of therapy.
Using EPR oximetry, the time course of pO2 changes
after an initial radiation dose in animal tumors has been
followed over periods of several weeks [ 85 ] . The typical time
pattern after irradiation has been an initial decrease post irradiation, followed by a subsequent increase in tumor pO2.
The biological significance for these changes was tested by
delivering split - dose radiation with the second dose timed to
coincide with the measured high or low point of pO2 post irradiation ( see Figure 5 ) . As shown in the figure, the
measured values of p O2 were predictive of the biological
effect. In fact, the effects of the split - dose regime delivered
at the time when the p O2 was at its high point post irradiation was at least as effective as if the radiation had
been delivered in a single dose, even though usually splitting
a dose of radiation lowers its efficacy.
These results suggest that EPR oximetry may be a useful
tool for optimizing the scheduling of radiation therapy by
enabling the therapist to deliver radiation doses at times
where the maximum effects would occur in the tumors.
Because at normal ( physiological ) levels of oxygen the
radiation response of cells does not change over a broad
range of oxygen concentrations and surrounding normal
tissues usually do not have hypoxic areas, the response of
the normal tissues adjacent to the tumor is not affected by
radiation - induced changes in the pO2. Therefore, by
optimizing the scheduling of radiation to coincide with
post - irradiation increases of oxygenation, the therapeutic
ratio should be increased.
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Figure 5. Effects of radiation on pO2 and volume of tumors. Twenty Gy of
ionizing radiation was given as a single dose or as a split dose with the interval
between the two 10 Gy doses determined by the time course of changes in
mean tumor pO2. Treatment groups were: 6 - Control ( Sham - Irradiated ) ; 5 Single ( 20 Gy at time 0 ) ; o - Oxygenated ( 10 Gy at time 0 and 10 Gy at 72
hours ) ; ~ - Hypoxic ( 10 Gy at time 0 and 10 Gy at 24 hours ) . Points are the
mean of five mice per group; error bars are SEM of measurements from five
tumors at each time point. Left side: Changes in pO2 as measured by EPR
oximetry. Right side: Tumor volume as determined by physical measurements
of three axes ( revised from Ref. [ 85 ] ) .

o

While these results are quite promising, additional studies in
animals and then in human patients will be required to
demonstrate the efficacy of this approach. Other techniques
that could provide similar data ( e.g., 19F MRI with
perfluorocarbons ) would be equally applicable; however,
their capability to assess reoxygenation has not been
established. The EPR technique described above can be
extended to report on the pO2 in several locations
simultaneously by the use of suitable gradients of the
magnetic field [ 86 ] . Using soluble stable free radicals, it
may be possible to obtain much more detailed maps of pO2
in tumors using EPR imaging [ 87 ] .
Modifiers of Tumor Oxygenation
Although tumor reoxygenation may lead to effective
radiotherapy in some tumors, in others, treatments designed to increase tumor oxygenation may be required.
Because the efficacy of tumor - oxygenating treatments
likely varies among tumors, non - invasive methods to
assess their impact are needed to guide their development
and clinical use. Several laboratories have used BOLD MRI
to detect large and reproducible T 2* increases in a number
of rodent tumor models during inhalation of pure oxygen
and carbogen [ 88 ± 93 ] . In at least one tumor model, the
R3230 mammary adenocarcinoma growing in Fisher rats
changes in T 2* during tumor - oxygenating treatments
averaged over the whole tumor strongly correlates with
changes measured with an oxygen microelectrode ( Ref.
[ 92 ] ; see Figure 6 ) . Moreover, in BA1112 tumors, BOLD
MRI correctly ranks the effects of three tumor - oxygenating
treatments [ carbogen alone, perfluorocarbon ( PFC ) emulsion injected intravenously, and the combination of carbogen and PFC ] on tumor hypoxic fraction [ 91 ] . This
experimental evidence supports the hypothesis that
changes in T 2* reflect changes in the oxygen saturation of
blood in tumors caused by tumor - oxygenating treatments
Ð and that this is strongly related to changes in
extravascular pO2 and hypoxic fraction.
MRI allows evaluation of spatial and temporal heterogeneity within tumors in their response to oxygenating
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Figure 6. Correlation of MR and oxygen microelectrode data: Water signal
peak height in a rodent mammary adenocarcinoma under control conditions.
The subsequent images show the difference between control images and the
change in water signal peak height during carbogen breathing. The changes
are spatially inhomogeneous and occur primarily in the tumor. The graphs
below show changes in pO2 measured by oxygen microelectrode during
carbogen breathing in the same tumor. The region in which MR signal peak
height does not change also shows no change in microelectrode current

treatments. In fact, MRI has provided some evidence that
some tumor regions respond paradoxically to oxygenating
treatments. Although there may be an increase in average
oxygenation, tumor - oxygenating treatments frequently decrease blood oxygenation in a small but significant fraction
of tumor volume as indicated by increased water signal
linewidth [ 92 ] . This may mean that some tumor regions
become more radioresistant during tumor - oxygenating
treatments, and cells in these regions may survive
radiation and repopulate the tumor following therapy.
Depending on the mechanism underlying these effects,
MRI could guide the formulation of tumor - oxygenating
treatments or combinations of tumor - oxygenating treatments which maximally increase oxygenation throughout
the entire tumor volume.
Oxygen challenges cause contrast changes in MRI
images which may be useful for diagnostic purposes.
Decreases in water signal linewidth in tumors caused by
tumor - oxygenating treatments are much more significant
than changes in surrounding normal tissues [ Refs. [ 88,89 ] ;
e.g., see Figure 6 ] . This may be because tumors are initially
hypoxic while normal tissue is not. Conversely, Vexler et al.
[ 94 ] showed that decreases in T 2* in rodent hepatic tumors
due to ischemia are much larger than T 2* decreases in
surrounding normal tissue; perhaps because the tumors
have insufficient blood supply. Thus, changes in T 2* in
response to increases or decreases in blood oxygenation
may help to identify tumor regions which are hypoxic or on
the verge of hypoxia. In general, changes in image contrast
in response to a variety of benign challenges, which affect
oxygenation and blood supply, may help to identify tumors
and characterize their physiology.
Use of EPR and MRI to measure tumor oxygenation and
changes in tumor oxygenation is a relatively new field that is
developing rapidly. The methods that are now being
developed and validated may have a significant impact on
the diagnosis and treatment of solid tumors in the coming
decade.

Gene Therapy
Gene therapy offers the possibility of curing disease by
correcting the genetic defects that underlie its pathogenesis.
As a genetic disease caused by multiple mutations in
growth - regulating genes in a single cell, cancer does not
seem amenable to this form of ``corrective'' gene therapy.
However, there has arguably been more success in cancer
gene therapy than any other type. There are currently over
200 cancer gene therapy protocols enrolling patients. The
majority of these novel therapeutic approaches do not aim
to correct the host of somatic mutations that lead to
oncogenesis, but rather aim to create therapeutically
exploitable phenotypic differences between normal and
malignant cells.
Two of the most widely studied cancer gene therapy
paradigms rely on expression of non - mammalian enzymes
that convert non - toxic prodrugs into cytotoxic metabolites.
Local expression of such prodrug - converting enzymes in
tumor tissue results in localized chemotherapy, aiming to
improve outcomes by minimizing the dose - limiting toxicity
associated with systemic chemotherapy. The first of these
``chemosensitization'' gene therapy approaches is based on
the preferential phosphorylation of the anti - herpetic drug,
ganciclovir, by the Herpes Simplex Virus thymidine kinase
( HSV - tk ) gene [ 95 ] . The other widely employed strategy
results in the production of the antimetabolite, 5 - FU, from
the antimycotic agent, 5 - fluorocytosine ( 5 - FC ) , by the
enzymatic action of microbial cytosine deaminase ( CD )
[ 96 ] .
Imaging of Transgene Expression
The ability to non - invasively measure the distribution,
magnitude and duration of therapeutic transgene expression
could have a profound impact on the development of cancer
gene therapy. Such assays would allow subject - by - subject
correlation of therapeutic efficacy with levels of transgene
expression, as was recently accomplished using radionuclide imaging [ 97 ] , and would be useful tools in the
development of vector technology. A recent study has
demonstrated the potential of MR spectroscopy for visualizing transgene expression in cancer cells [ 98 ] . In this study,
the enzymatic activity of yeast CD expressed in subcutaneous tumors was quantified with 19F MRS to observe the
conversion of 5 - FC to 5 - FU. This study was the first direct
confirmation that an enzyme / prodrug gene therapy paradigm results in local chemotherapy ( see Figure 7 ) . Future
studies may provide data on the feasibility of obtaining 19F
MR images of the metabolites within the tumor tissue that
would allow for regional assessment of CD delivery for
correlation with therapeutic response.
While a variety of delivery vehicles have been utilized for
delivering transgenes to tumor cells, viral vectors have been
the most widely used vector systems. Viral vectors have
similar dimensions as monocrystalline iron oxide ( MION )
particles which are used as an MRI contrast agent. MR has
been reported useful for imaging the distribution of viral
vectors as they have been shown to have essentially the
same tissue distribution as MION particles [ 99 ] . Additional
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in tumor water ADC can be observed following gene
therapy [ 32,33 ] . Finally, changes in MRS - observable
proton metabolites following HSV - tk gene therapy have
also been reported [ 32,103 ] . Taken together, these
studies reveal that a variety of significant gene therapy induced effects can be non - invasively observed in tumor
models using MRI / S.

Figure 7. Representative in vivo 19F spectra from subcutaneous tumors
obtained 120 ± 150 minutes following i.p. injection of 1 g kg 1 5 - FC. A single
peak of 5 - FC is observed in the parental HT29 carcinoma ( A ) . In contrast,
the HT29 carcinoma expressing yCD ( B ) converted the 5 - FC to 5 - FU, which
was subsequently metabolized into fluorinated nucleotides ( Fnuc ) . Fluoro - alanine ( F Al ) , a catabolic breakdown product of 5 - FU, was also
observed in this tumor. Reprinted from Stegman L.D. et al. [ 98 ] . Non invasive detection of cytosine deaminase transgene expression in human
tumor xenografts with in vivo magnetic resonance spectroscopy [ PNAS 96:
9821 ± 9826. National Academy of Sciences, U.S.A. Copyright ( 1999 ) . ]

strategies for using MRI to detect gene delivery have been
demonstrated in vitro using specific marker genes such as
melanin [ 100 ] and the human transferrin receptor [ 101 ] .
Therapeutic Assessment of Gene Therapy
Small animal tumor models are used for the pre - clinical
evaluation of the anti - neoplastic efficacy of experimental
gene therapy paradigms. The use of MRI and MRS for
evaluating the effects of gene therapy on tumor physiology, biology, biochemistry, and morphology has been
reported. Studies using orthotopic tumor models have
benefited from the use of MR, which provides the ability to
demarcate the location and size of the tumor prior to gene
delivery. This has been used for the guiding the delivery of
both retroviral [ 102 ] and adenoviral [ 103 ] vectors into
intracerebral glioma models. Changes in tumor volumes
and growth rates following gene therapy protocols in
orthotopic tumor models have also proven beneficial for
assessing therapeutic efficacy [ 96,103 ± 106 ] . In addition
to using MR to assess changes in morphometry, recent
studies using diffusion MRI ( see Early Detection of
Therapeutic Response section ) have shown that changes
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Anti - Vascular Therapy
Anti - vascular cancer therapy is here defined as a treatment
acting primarily via effects on development or function of
tumor blood vessels. Its potential advantages include the
following. 1 ) Damage to a small number of vascular
endothelial cells could result in the death of a large number
of tumor cells which depend on them for the supply of
nutrients. 2 ) It is easier to deliver drugs to vascular
endothelial cells than to cells in solid tumors. 3 ) Tumor
vasculature is a new target so agents should have a new
spectrum of toxicities. 4 ) Inhibition of formation of new blood
vessels ( anti - angiogenic therapy ) may slow or prevent
metastatic spread or growth of micro - metastases. Because
MR can non - invasively assess tumor vascularity and
energetics, it provides a powerful tool for the pre - clinical
development of anti - vascular therapy that can be readily
translated into clinical use.
Vaso - Active Agents
Several vaso - active agents, in particular hydralazine,
have been shown to result in a selective reduction in tumor
perfusion in transplanted animal tumors and, in some cases,
also in primary tumors in animals [ e.g. Ref. [ 107 ] ] . 31P MRS
has been widely applied in such studies for non - invasive
monitoring of the metabolic consequences of an acute
reduction in tumor blood flow ( fall in NTP, increase in Pi and
often a decrease in pH ) . The mechanism of action is
generally believed to involve vasodilatation of normal
peripheral blood vessels, resulting in a reduction in arterial
blood pressure and a ``steal effect'' of blood away from the
tumor ( tumor vessels may not respond normally because of
a lack of smooth muscle and / or appropriate receptors ) . The
high interstitial pressure of tumors may also contribute to the
collapse of some vessels when blood pressure falls. Since
the blood flow and metabolic effects of this approach are
generally short - lived and do not normally cause permanent
damage to tumor blood vessels, they are not normally
included as anti - vascular agents.
Cytokines and Cytokine - Releasing Agents
Vascular damage has been shown to be an important
feature of treatments with the cytokines TNF - [ 108 ] and
IL - 1 [ 109 ] . These cytokines resulted in hemorrhage
( determined histologically ) and an attenuation of tumor
energetic status ( 31P MRS ) . Flavone acetic acid ( FAA ) was
probably the first anti - cancer drug shown to act predominantly via tumor vascular damage. Evelhoch et al. [ 110 ]
demonstrated that FAA caused a reduction in bioenergetic
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status ( 31P MRS measurement of NTP / Pi ) and in tumor
blood flow ( 2H MRS measurement of D2O clearance ) . Su et
al. [ 44 ] measured the uptake of Gd - DTPA and a macromolecular MR contrast agent ( gadomer - 17, 35 kDa ) in a rat
adenocarcinoma before treatment and after a combination of
Mitomycin - C and FAA. The kinetics of Gadomer - 17 was
used to calculate tumor vascular volume, which was reduced
by 42% 4 days after treatment in responding tumors.
Unfortunately, the pre - clinical success with FAA was not
translated into the clinic, possibly because FAA acted via
causing a release of TNF in the mouse but did not lead to
TNF release in humans. A more potent analogue of FAA,
dimethylxanthenone acetic acid ( DMXAA ) , has been
developed which can cause TNF release in humans. 31P
MRS has been used to follow the time course and dose dependency of DMXAA effects in murine C3H mammary
tumors [ 111 ] while DCE - MRI studies ( uptake of Gd DTPA ) have been included in phase I clinical trials of
DMXAA and preliminary results showed a reduction in both
the rate and magnitude of Gd - DTPA uptake 24 hours post treatment in 7 out of 10 patients [ 112 ] .
Tubulin - Binding Agents
Combretastatin is a tubulin - binding agent with anti angiogenic and anti - vascular properties. Beauregard et al.
[ 113 ] used 31P MRS and several MRI approaches to study
the effects of combretastatin ( 100 mg kg 1 ) on subcutaneous sarcoma F tumors in mice. They observed a fall in
energetic status ( reported as a two - fold increase in Pi /
NTP ) 150 minutes after treatment and a fall in tumor pH. The
rate of uptake of Gd - DTPA into the tumor center was
decreased 2.5 - fold at 160 minutes with a smaller effect
reported for the tumor periphery. Changes in T 2 - weighted
images ( i.e., slight increases in the area of low signal
intensity regions ) 180 minutes after treatment were ascribed
to hemorrhage, consistent with histological changes in these
tumors. The tumor water ADC was measured before and up
to 1.8 hours after treatment but no significant changes were
detected. Maxwell et al. [ 114 ] used MRS and MRI
techniques to study the effects of combretastatin ( 100 mg
kg 1 ) on C3H mammary tumors implanted on the mouse
foot. The 31P MRS results were similar to those of
Beauregard et al. [ 113 ] ( marked fall in NTP / Pi ) although
an additional measurement at 24 hours after treatment
showed full recovery of NTP / Pi. Single - voxel 1H MRS
measurements of lactate did not show a consistent increase,
possibly due to lipid contamination and / or a reduction in
glucose supply associated with blood flow reduction. No
increase in low signal intensity regions of T 2 - weighted MR
images was detected within 3 hours of combretastatin
treatment. In the case of the C3H mammary tumor, histology
showed no significant increase in tumor necrosis 3 hours after
treatment although an increase in necrosis from 2% to 16%
was observed at 24 hours. The extent of hemorrhagic
necrosis may vary between anti - vascular therapies and
tumor types but these data imply that hemorrhage is not a
pre - requisite for combretastatin - induced tumor blood flow
reduction.

Future Development of Anti - Vascular Agents
Given the availability of MR methods relevant to the
actions of anti - vascular drugs, it is both feasible and
desirable to include MR end points as part of the pre clinical and clinical evaluation of such agents. However,
several complicating factors should be taken into account.
1 ) The analysis of Gd - DTPA kinetics may be complicated
by drugs which act both to decrease perfusion and to
increase vascular permeability. Freely diffusible tracers
( e.g. D2O for animal studies ) and blood - pool contrast
agents may give more specific information. 2 ) Conflicting
effects of hemorrhagic necrosis and edema may be seen
in MR images. 3 ) Lacate - edited 1H MRS is relatively
sensitive and specific but lactate changes may be
attenuated by limited glucose supply. 4 ) 31P MRS is
relatively insensitive but has been valuable for monitoring
the effects of vaso - active and vascular - damaging agents
in animal tumors. There may be a threshold of blood flow
reduction and / or a delay before effects on energy
metabolism are observed. 5 ) A range of MRI tools for
studying angiogenesis has been introduced [ e.g., Abramovitch et al. [ 115 ] , Sipkins et al. [ 116 ] ] and may be
useful for evaluating anti - angiogenic drugs. High spatial
resolution will be needed and micro - metastases may be
difficult or impossible ( at the present time ) to detect.

Summary
Magnetic resonance can non - invasively provide a wealth of
information regarding tumor metabolism and pathophysiology. As a consequence, it has contributed to our understanding of both the effects of treatment on tumor
metabolism and pathophysiology and the importance of
tumor metabolism and pathophysiology as determinants of
therapeutic response. MR has made substantial contributions in these areas including several discussed in this
review. MR can readily monitor changes such as cell
shrinkage, already known to occur during apoptosis, and
previously unappreciated metabolic changes associated with
upstream steps in the apoptotic pathway have been
identified. MR measurable changes in tumor water ADC
induced by cytotoxic therapy, which appear to be associated
with changes in tumor pathophysiology due to cell death,
may be generally applicable for early detection of response
to cytotoxic therapy. DCE - MRI is a practical tool for non invasive evaluation of changes in tumor vascularity following
cancer therapy and may provide an early indication of
therapeutic response. The metabolic information provided by
MR allows evaluation of the pharmacodynamics of metabolic
inhibitors that can help to optimize their use as potential anti neoplastic agents or sensitizers. 31P MRS measurement of
pHe and pHi simultaneously demonstrates for the first time in
vivo that raising the plasmalemmal pH gradient with sodium
bicarbonate in drinking water leads to significant improvements in the therapeutic effectiveness of doxorubicin against
MCF - 7 xenografts. Non - invasive assessment of tumor
oxygenation with EPR and MRI allows the effects of
modulating hypoxia to be considered in the timing of
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subsequent doses of radiotherapy. 19F MRS quantitation of
the enzymatic activity of yeast CD expressed in subcutaneous tumors by observing the conversion of 5 - FC to 5 - FU
is the first direct confirmation that an enzyme / prodrug gene
therapy paradigm results in local chemotherapy. Because in
vivo tumor metabolism and pathophysiology can be assessed non - destructively by MR, pre - clinical results from
cellular or animal models are often easily translated into the
clinic. Hence, these MR techniques, which have distinct
advantages over other proposed and currently implemented
techniques, have the potential to revolutionize treatment
monitoring.
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